Showing results (111-120 of 167) with videos related to
Sort By:
Pageof 17
Therapeutic Advances in Medical Oncology|March 6, 2023
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)Louise Emmett, Nikeith John, Sarennya Pathmanandavel, et al.International Journal of Cancer|July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.The Oncologist|June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyFelicia T Roncolato, Florence Joly, Rachel O'Connell, et al.Gynecologic Oncology|November 7, 2017
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)Felicia T Roncolato, Dominique Berton-Rigaud, Rachel O'Connell, et al.Journal for Immunotherapy of Cancer|June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trialYoland Antill, Peey-Sei Kok, Kristy Robledo, et al.The Lancet. Oncology|October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialJames P Buteau, Andrew J Martin, Louise Emmett, et al.Cancer Chemotherapy and Pharmacology|October 29, 2018
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)Kristina Lindemann, Philip J Beale, Emma Rossi, et al.Cancers|January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)Deborah Smith, Kristy P Robledo, Sonia Yip, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancerMadeleine T King, Martin R Stockler, Rachel L O'Connell, et al.Nature Communications|February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATELavinia Tan, Chris Brown, Antony Mersiades, et al.Pageof 17